NCT06879158

A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions

A Randomized, Open-label, Fasting, Single Dose, Two-way Crossover Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

The purpose of this clinical study is to evaluate the pharmacokinetics and safety of BR3409 and co-administration of BR3409-1 and BR3409-2 in healthy volunteers Under Fasting Conditions

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	BR3409	One tablet administered alone
DRUG	BR3409-1	One tablet administered alone
DRUG	BR3409-2	One tablet administered alone

Timeline

• Start date: 2024-11-10
• Primary completion: 2025-01-26
• Completion: 2025-01-26
• First posted: 2025-03-17
• Last updated: 2025-03-17

Locations

1 site across 1 country: South Korea